{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:24:34Z","timestamp":1761708274063},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuraminidase inhibitors (NI) play a major role in plans to mitigate future influenza pandemics. Modeling studies suggested that a pandemic may be contained at the source by early treatment and prophylaxis with antiviral drugs. Here, we examine the influence of NI resistant influenza strains on an influenza pandemic. We extend the freely available deterministic simulation program<jats:italic>InfluSim<\/jats:italic>to incorporate importations of resistant infections and the emergence of<jats:italic>de novo<\/jats:italic>resistance. The epidemic with the fully drug sensitive strain leads to a cumulative number of 19,500 outpatients and 258 hospitalizations, respectively, per 100,000 inhabitants. Development of<jats:italic>de novo<\/jats:italic>resistance alone increases the total number of outpatients by about 6% and hospitalizations by about 21%. If a resistant infection is introduced into the population after three weeks, the outcome dramatically deteriorates. Wide-spread use of NI treatment makes it highly likely that the resistant strain will spread if its fitness is high. This situation is further aggravated if a resistant virus is imported into a country in the early phase of an outbreak. As NI-resistant influenza infections with high fitness and pathogenicity have just been observed, the emergence of drug resistance in treated populations and the transmission of drug resistant strains is an important public health concern for seasonal and pandemic influenza.<\/jats:p>","DOI":"10.1186\/1743-422x-5-133","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T19:13:24Z","timestamp":1225394004000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modeling the effects of drug resistant influenza virus in a pandemic"],"prefix":"10.1186","volume":"5","author":[{"given":"Stefan O","family":"Brockmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Schwehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Witschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Vidondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Eichner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,30]]},"reference":[{"key":"482_CR1","unstructured":"Strengthening pandemic-influenza preparedness and response, including application of the International Health Regulations (2005). Fifty-ninth World Health Assembly. WHO document A59\/4[http:\/\/www.who.int\/gb\/ebwha\/pdf_files\/WHA59\/A59_4-en.pdf]"},{"key":"482_CR2","unstructured":"Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA)[http:\/\/www.emea.europa.eu\/htms\/human\/pandemicinfluenza\/antivirals.htm]"},{"key":"482_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1128\/AAC.01339-05","volume":"50","author":"AS Monto","year":"2006","unstructured":"Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M: Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006, 50: 2395-2402. 10.1128\/AAC.01339-05","journal-title":"Antimicrob Agents Chemother"},{"key":"482_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1086\/424572","volume":"190","author":"ML Herlocher","year":"2004","unstructured":"Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS: Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004, 190: 1627-1630. 10.1086\/424572","journal-title":"J Infect Dis"},{"key":"482_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1086\/515246","volume":"177","author":"NI Stilianakis","year":"1998","unstructured":"Stilianakis NI, Perelson AS, Hayden FG: Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. J Infect Dis 1998, 177: 863-873.","journal-title":"J Infect Dis"},{"key":"482_CR6","unstructured":"Interim ECDC Risk Assessment \u2013 Emergence of seasonal influenza viruses type A\/H1N1 with oseltamivir resistance in some European Countries at the start of the 2007\u20138 influenza season[http:\/\/www.ecdc.europa.eu\/pdf\/080127_os.pdf]"},{"key":"482_CR7","doi-asserted-by":"crossref","unstructured":"Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008.,13(5):","DOI":"10.2807\/ese.13.05.08026-en"},{"key":"482_CR8","unstructured":"Update A(H1N1) viruses resistant to oseltamivir[http:\/\/www.eiss.org\/html\/lb_h1n1_resistance_oseltamivir.html]"},{"issue":"Suppl 1","key":"482_CR9","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/jac\/dki018","volume":"55","author":"P Ward","year":"2005","unstructured":"Ward P, Small I, Smith J, Suter P, Dutkowski R: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005,55(Suppl 1):i5-i21. 10.1093\/jac\/dki018","journal-title":"J Antimicrob Chemother"},{"key":"482_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","volume":"20","author":"RJ Whitley","year":"2001","unstructured":"Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P: Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20: 127-133. 10.1097\/00006454-200102000-00002","journal-title":"Pediatr Infect Dis J"},{"key":"482_CR11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","volume":"12","author":"FY Aoki","year":"2007","unstructured":"Aoki FY, Boivin G, Roberts N: Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007, 12: 603-616.","journal-title":"Antivir Ther"},{"key":"482_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/096228029300200103","volume":"2","author":"K Dietz","year":"1993","unstructured":"Dietz K: The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res 1993, 2: 23-41. 10.1177\/096228029300200103","journal-title":"Stat Methods Med Res"},{"key":"482_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2334-7-17","volume":"7","author":"M Eichner","year":"2007","unstructured":"Eichner M, Schwehm M, Duerr HP, Brockmann SO: The influenza pandemic preparedness planning tool InfluSim . BMC Infect Dis 2007, 7: 17. 10.1186\/1471-2334-7-17","journal-title":"BMC Infect Dis"},{"key":"482_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2334-7-76","volume":"7","author":"HP Duerr","year":"2007","unstructured":"Duerr HP, Brockmann SO, Piechotowski I, Schwehm M, Eichner M: Influenza pandemic intervention planning using InfluSim: pharmaceutical and non-pharmaceutical interventions. BMC Infect Dis 2007, 7: 76. 10.1186\/1471-2334-7-76","journal-title":"BMC Infect Dis"},{"key":"482_CR15","first-page":"CD006207","volume-title":"Cochrane Database Syst Rev","author":"T Jefferson","year":"2007","unstructured":"Jefferson T, Foxlee R, Del Mar C, Dooley L, Ferroni E, Hewak B, Prabhala A, Nair S, Rivetti A: Interventions for the interruption or reduction of the spread of respiratory viruses. Cochrane Database Syst Rev 2007, CD006207."},{"key":"482_CR16","doi-asserted-by":"publisher","first-page":"e2618","DOI":"10.1371\/journal.pone.0002618","volume":"3","author":"Mvan der Sande","year":"2008","unstructured":"Sande M, Teunis P, Sabel R: Professional and home-made face masks reduce exposure to respiratory infections among the general population. PLoS ONE 2008, 3: e2618. 10.1371\/journal.pone.0002618","journal-title":"PLoS ONE"},{"key":"482_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1098\/rsif.2006.0161","volume":"4","author":"G Chowell","year":"2007","unstructured":"Chowell G, Nishiura H, Bettencourt LM: Comparative estimation of the reproduction number for pandemic influenza from daily case notification data. J R Soc Interface 2007, 4: 155-166. 10.1098\/rsif.2006.0161","journal-title":"J R Soc Interface"},{"key":"482_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature04017","volume":"437","author":"NM Ferguson","year":"2005","unstructured":"Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005, 437: 209-214. 10.1038\/nature04017","journal-title":"Nature"},{"key":"482_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/aje\/kwh092","volume":"159","author":"IM Longini Jr","year":"2004","unstructured":"Longini IM Jr, Halloran ME, Nizam A, Yang Y: Containing pandemic influenza with antiviral agents. Am J Epidemiol 2004, 159: 623-633. 10.1093\/aje\/kwh092","journal-title":"Am J Epidemiol"},{"key":"482_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/jac\/dkg136","volume":"51","author":"NM Ferguson","year":"2003","unstructured":"Ferguson NM, Mallett S, Jackson H, Roberts N, Ward P: A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother 2003, 51: 977-990. 10.1093\/jac\/dkg136","journal-title":"J Antimicrob Chemother"},{"key":"482_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1126\/science.1122947","volume":"312","author":"RR Regoes","year":"2006","unstructured":"Regoes RR, Bonhoeffer S: Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006, 312: 389-391. 10.1126\/science.1122947","journal-title":"Science"},{"key":"482_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1365-2044.2005.04372.x","volume":"60","author":"DK Menon","year":"2005","unstructured":"Menon DK, Taylor BL, Ridley SA: Modelling the impact of an influenza pandemic on critical care services in England. Anaesthesia 2005, 60: 952-954. 10.1111\/j.1365-2044.2005.04372.x","journal-title":"Anaesthesia"},{"key":"482_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virusres.2004.02.007","volume":"103","author":"ML van Genugten","year":"2004","unstructured":"van Genugten ML, Heijnen ML: The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands. Virus Res 2004, 103: 17-23. 10.1016\/j.virusres.2004.02.007","journal-title":"Virus Res"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-5-133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:54:04Z","timestamp":1684616044000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-5-133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-5-133","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,30]]},"assertion":[{"value":"5 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"133"}}